Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the Independent Medicines and Medical Devices Safety Review report, published on 8 July 2020, if he will make an assessment of the potential merits of launching a public inquiry into the potential harms of anti-seizure medication.

Everyone who has been harmed following use of anti-seizure medication has our deepest sympathies. We fully understand the importance of patient safety, which is a top priority for this government. It is vital we do all we can to stop harm from happening in the first place.

The Medicines and Healthcare products Regulatory Agency rigorously monitors and reviews all emerging data and risks in relation to anti-seizure medication and communicates information on risks to patients. Following Baroness Cumberlege’s 2020 Independent Medicines and Medical Devices Safety (IMMDS) Review, which examined the anti-seizure medication Sodium Valproate in detail, several actions have been taken to ensure that valproate is only prescribed when clinically appropriate. These include ensuring valproate is not started in new patients younger than 55 years old unless two specialists independently consider and document that there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply.

One of the conclusions of the IMMDS Review was that a public inquiry would not best serve the interests of those affected by each of the interventions covered by the review. We have no plans to launch a public inquiry into the potential harms of anti-seizure medication.